A Prospective Study of Azilsartan Medoxomil in the Treatment of Patients With Essential Hypertension and Type 2 Diabetes in Asia

Trial Profile

A Prospective Study of Azilsartan Medoxomil in the Treatment of Patients With Essential Hypertension and Type 2 Diabetes in Asia

Completed
Phase of Trial: Phase IV

Latest Information Update: 07 Feb 2017

At a glance

  • Drugs Azilsartan medoxomil (Primary)
  • Indications Essential hypertension; Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Sponsors Takeda
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 26 Jan 2017 Status changed from recruiting to completed.
    • 28 Jul 2016 Planned patient no changed from 494 to 363.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top